Hemophilic Arthropathy Clinical Trial
Official title:
A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
Repeated joint bleeding leads to hemophilic arthropathy (HA), which manifests with chronic synovitis, cartilage damage and bony destruction. Currently available treatments of HA, including analgesics, NSAIDs, and hyaluronic acid, are predominantly directed toward the symptomatic relief of pain and inflammation, with no or little effect on joint cartilage degeneration. AC201CR, a control released formulation of AC-201, demonstrates anti-inflammatory effects by reducing NLRP3 inflammasome assembly. AC-201 is also unique in that it influences both the anabolism and catabolism of chondrocytes in vitro and has shown cartilage-sparing properties in animal studies. The study is designed to evaluate the joint structure-modifying and symptom-relieving effects, safety, and tolerability of AC-201CR in subjects with HA.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01232634 -
Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
|
Phase 2 | |
| Completed |
NCT02601170 -
Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
|
N/A | |
| Terminated |
NCT04684511 -
Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy
|
Phase 3 | |
| Recruiting |
NCT05517070 -
Vitamin D Deficiency and Body Composition in the Patients With Hemophilia
|
||
| Completed |
NCT04297696 -
The Effects of Exercises on Gait in Hemophilic Individuals
|
N/A | |
| Completed |
NCT04535180 -
Sarcopenia and Osteoporosis in the Patients With Hemophilia
|
||
| Terminated |
NCT02569359 -
Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy
|
N/A |